Biocon also has strategic relationships with multinational companies in different areas. It is in collaboration with Bristol-Myers Squibb for research services that leverages high quality scientific talent; co-development for Mylan that enables risk and resource sharing; and R&D partnering for Optimer that accelerates innovation in a cost-effective manner.

In the long run, partnerships between global companies and Asian firms will lead to uniformity in drug pricing, strong IP protection and global harmonization. And if there is a clash of interest and priorities, the companies need to have other avenues, for example a strong brand, to sail through the situation as is being expected of Biocon.